Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (11-20 of 199) with videos related to

Pageof 20
Sort By:
Cancer|January 29, 2010
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survivalGeoffrey R Oxnard, Lawrence H Schwartz
JAMA Oncology|July 21, 2018
Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing AssaysGeoffrey R Oxnard, Cloud P Paweletz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypesGeoffrey R Oxnard, Pasi A Jänne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
KRAS wild-type lung cancer: a moving target in an era of genotype migrationGeoffrey R Oxnard, Pasi A Jänne
JAMA Oncology|May 19, 2017
Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain MetastasesPablo Martínez, Raymond H Mak, Geoffrey R Oxnard
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agentsHoward West, Geoffrey R Oxnard, Robert C Doebele
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
New targetable oncogenes in non-small-cell lung cancerGeoffrey R Oxnard, Adam Binder, Pasi A Jänne
Chinese Clinical Oncology|September 27, 2015
Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trialsRyan S Alden, Sumithra J Mandrekar, Geoffrey R Oxnard
JAMA Oncology|July 9, 2016
Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-ReplyAdrian G Sacher, Ryan S Alden, Geoffrey R Oxnard
Cancer Research|July 2, 2020
Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid BiopsyLynette M Sholl, Geoffrey R Oxnard, Cloud P Paweletz
Pageof 20

Showing results (11-20 of 199) with videos related to

Sort By:
Pageof 20
Cancer|January 29, 2010
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survivalGeoffrey R Oxnard, Lawrence H Schwartz
JAMA Oncology|July 21, 2018
Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing AssaysGeoffrey R Oxnard, Cloud P Paweletz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypesGeoffrey R Oxnard, Pasi A Jänne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
KRAS wild-type lung cancer: a moving target in an era of genotype migrationGeoffrey R Oxnard, Pasi A Jänne
JAMA Oncology|May 19, 2017
Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain MetastasesPablo Martínez, Raymond H Mak, Geoffrey R Oxnard
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agentsHoward West, Geoffrey R Oxnard, Robert C Doebele
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
New targetable oncogenes in non-small-cell lung cancerGeoffrey R Oxnard, Adam Binder, Pasi A Jänne
Chinese Clinical Oncology|September 27, 2015
Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trialsRyan S Alden, Sumithra J Mandrekar, Geoffrey R Oxnard
JAMA Oncology|July 9, 2016
Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-ReplyAdrian G Sacher, Ryan S Alden, Geoffrey R Oxnard
Cancer Research|July 2, 2020
Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid BiopsyLynette M Sholl, Geoffrey R Oxnard, Cloud P Paweletz
Pageof 20